Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16964293 | 1.00 | ALDH1A1 (0.38) | ALDH1A1TSHRCYP2D6CYP2C19TP53 | |
| SCHEMBL16876467 | 1.00 | ALDH1A1 (0.38) | ALDH1A1TSHRCYP2D6CYP2C19TP53 | |
| SCHEMBL15619355 | 1.00 | ALDH1A1 (0.38) | ALDH1A1TSHRCYP2D6CYP2C19TP53 | |
| SCHEMBL16165213 | 0.79 | CYP2D6 (0.36) | ALDH1A1TSHRCYP2D6CYP2C19TP53 | |
| SCHEMBL20501441 | 0.79 | CYP2D6 (0.36) | ALDH1A1TSHRCYP2D6CYP2C19TP53 | |
| SCHEMBL20514366 | 0.78 | CYP2D6 (0.38) | ALDH1A1TSHRCYP2D6CYP2C19 | |
| SCHEMBL20514367 | 0.78 | CYP2D6 (0.38) | ALDH1A1TSHRCYP2D6CYP2C19 | |
| SCHEMBL16876210 | 0.78 | CYP2D6 (0.38) | ALDH1A1TSHRCYP2D6CYP2C19 | |
| SCHEMBL5631671 | 0.77 | GABRR1 (0.34) | CYP2D6CYP2C19TP53 | |
| SCHEMBL16164213 | 0.77 | ALDH1A1 (0.42) | ALDH1A1CYP2D6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7291744-B2 | N-ureidoalkyl-amino compounds as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-11-06 | — | — | US | disclosed |
| US-20050153970-A1 | N-ureidoalkyl-amino compounds as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY | 2005-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050153970-A1 | N-ureidoalkyl-amino compounds as modulators of chemokine receptor activity | ACKR3, CCL11, GPR17 | ALDH1A1 1127/4885TSHR 1476/4885CYP2D6 3192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.